Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Juliann Chmielecki, Jhanelle E. Gray*, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J. Carl Barrett, Ryan J. Hartmaier, Suresh S. Ramalingam

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

Abstract

Correction to: Nature Communications, published online 27 February 2023 The original Article contained errors in the legend of Figure 3 that incorrectly read “Comparator EGFR-TKI duration of treatment by candidate resistance mechanisms. Swimmer plot indicating duration of treatment with comparator EGFR-TKI (months) by resistance mechanisms (n = 145).”. This has been corrected and the legend now reads: “Osimertinib duration of treatment by candidate resistance mechanisms. Swimmer plot indicating duration of treatment with osimertinib (months) by resistance mechanisms (n = 109 total, n = 38 with detected resistance mutation).” Two statements in the Discussion section contained errors and have also been amended. In the third paragraph, the original sentence “The frequency of MET amplification (16%) was similar to that observed in patients treated with second-line osimertinibin the Phase III AURA3 study (19%)” should have read “The frequency of MET amplification (16%) was similar to that observed in patients treated with second-line osimertinibin the Phase III AURA3 study (18%)”. In the fourth paragraph, the original sentence “An analysis of second-line osimertinib in the Phase I AURA13 (n=6) and Phase III AURA314,15 studies identified 14% of patients acquired EGFR C797S” should have read “An analysis of second-line osimertinib in the Phase III AURA314,15 study identified 14% of patients acquired EGFR C797S”. In addition, inadvertently, data from a patient with an acquired BRAF D594N mutation (already included in Figure 2B) were not displayed in Supplementary Figure 1. The figure and its legend have been updated accordingly in the Supplementary Information file. The original sentence in the Figure legend “Swimmer plot indicating duration of treatment with comparator EGFR-TKI (months) by resistance mechanisms (n=145 total)” now reads “Swimmer plot indicating duration of treatment with comparator EGFR-TKI (months) by resistance mechanisms (n=145 total, n = 71 with detected resistance mutation)”. These changes do not affect the scientific conclusions of this work. Errors have been corrected in the PDF and HTML versions of the Article. The HTML has been updated to include a corrected version of the Supplementary Information.

Original languageEnglish
Article number3179
Pages (from-to)3179
JournalNature Communications
Volume14
Issue number1
DOIs
StatePublished - 01 06 2023
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2023, The Author(s).

Fingerprint

Dive into the research topics of 'Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this